Schipor Sorina, Publik Mihai Alin, Manda Dana, Ceausu Mihail
Department of Research, "C.I. Parhon" National Institute of Endocrinology, 011863 Bucharest, Romania.
Department of Pathology, "C.I. Parhon" National Institute of Endocrinology, 011863 Bucharest, Romania.
Int J Mol Sci. 2025 Jun 10;26(12):5535. doi: 10.3390/ijms26125535.
Aggressive thyroid carcinomas are rare malignancies characterized by a high impact on patient's lives and poor prognosis. The available literature is scarce presenting divergent data concerning the clinical outcomes, prognostic factors and variable mutational signature studies. We aim to collect data from the literature and assemble a systematic review. The literature from 2007 until May 2025 was searched using PubMed. Studies bearing data concerning clinical aspects, prognostic outcomes, or molecular characteristics of differentiated high-grade (DHGTC), poorly differentiated (PDTC), and anaplastic thyroid carcinomas (ATC) were retrieved. Original articles in English, ethically conducted on human patients, were selected. From 688 articles, 39 were included. has a good 5-year survival rate (5YSR) of 76%, 23.18% metastasis rate, 42.23%, lymph node involvement (LNI), 61.44% extrathyroidal extension (ETE), majority being diagnosed in stage III. has an intermediate 5YSR of 65.71%, 21.17% distant metastasis, 32.22% LNI, and 55.19% ETE, majority diagnosed in stage III. has a grim 2-year survival rate of 11.15%, 42.15% metastasis, 44.14%, LNI, and 58.51% ETE, majority presented in stage IV-B. Mutational profiling shows that each carcinoma has its unique set of molecular alterations. Most positive prognostic comes for DHGTC, then PDTC, and finally, ATC.
侵袭性甲状腺癌是罕见的恶性肿瘤，其特点是对患者生活影响大且预后差。现有文献稀缺，关于临床结局、预后因素和可变突变特征研究的数据存在分歧。我们旨在从文献中收集数据并进行系统综述。使用PubMed搜索了2007年至2025年5月的文献。检索了包含分化型高级别（DHGTC）、低分化（PDTC）和未分化甲状腺癌（ATC）临床方面、预后结局或分子特征数据的研究。选择了以英文撰写的、符合伦理规范的关于人类患者的原创文章。在688篇文章中，纳入了39篇。DHGTC的5年生存率（5YSR）良好，为76%，转移率为23.18%，淋巴结受累（LNI）为42.23%，甲状腺外侵犯（ETE）为61.44%，大多数在III期被诊断。PDTC的5YSR中等，为65.71%，远处转移为21.17%，LNI为32.22%，ETE为55.19%，大多数在III期被诊断。ATC的2年生存率严峻，为11.15%，转移率为42.15%，LNI为44.14%，ETE为58.51%，大多数在IV - B期出现。突变谱分析表明，每种癌都有其独特的分子改变集。预后最积极的是DHGTC，其次是PDTC，最后是ATC。
